NCT05282446View on ClinicalTrials.gov

A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 11, 2022

Study Completion Date

October 1, 2022

Conditions
Metabolic Syndrome
Interventions
DRUG

INV-202

tablet

DRUG

Placebo

matching tablet

Trial Locations (1)

G1P 0A2

Syneos Health Clinique Inc, Québec

Sponsors
All Listed Sponsors
lead

Inversago Pharma Inc.

INDUSTRY